28558-00-1

Basic information

• Product Name: (6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one
• CAS NO: 28558-00-1
• Molecular Formula: C₂₀H₃₀O₃
• Molecular Weight: 318.4504
• Mol File: 28558-00-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 480.2°C at 760 mmHg
• Flash Point: 258.3°C
• Density: 1.17g/cm³
• Vapor Pressure: 3.09E-11mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: (6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one(28558-00-1)
• EPA Substance Registry System: (6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one(28558-00-1)

Safety Data

• Hazardous Substances Data: 28558-00-1(Hazardous Substances Data)

Usage

General Description

The chemical (6alpha,11beta,17beta)-11,17-dihydroxy-6-methylandrost-4-en-3-one, also known as 11-beta,17-beta-dihydroxy-6-alpha-methyl-4-androstadien-3-one, is a steroid hormone and a natural metabolite of dehydroepiandrosterone (DHEA). It is produced in the adrenal glands and acts as a precursor to the sex hormones, including testosterone and estrogen. This chemical is involved in various physiological processes, such as the regulation of immune function, energy metabolism, and stress response. It also plays a role in the development and maintenance of reproductive tissues and sexual characteristics. Additionally, it has been studied for its potential therapeutic benefits in conditions such as aging, obesity, and autoimmune diseases.

Upstream product

• 110247-89-7 5,11β-dihydroxy-6β-methyl-5α-androstane-3,17-dione 
• 115099-19-9 11β-hydroxy-6-methyl-3-pyrrolidino-androsta-3,5-dien-17-one 

Relevant articles and documents

ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT

The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

Method for androgen supplementation

A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.